We are proud to announce that the American Medical Association (AMA) has accepted our PLA Code application for MiCheck® Prostate. This next-generation blood test helps urologists identify the risk of clinically significant prostate cancer.
Effective October 1, 2025, MiCheck® Prostate has been assigned a Proprietary Laboratory Analyses (PLA) code 0591U.
This milestone is a critical step in expanding access to MiCheck® Prostate across the U.S. It strengthens our efforts to secure reimbursement, increase adoption, and deliver better diagnostic tools for physicians and patients alike.
“Receiving a PLA code from the AMA is a major inflection point in our U.S. expansion,” said Sushmita Utpala, Global Chief Operating Officer of Minomic. “It validates the clinical value of MiCheck® Prostate and positions us to accelerate our reimbursement strategy and scale adoption among urologists nationwide.”
Brad Walsh, CEO, said, “Minomic is dedicated to advancing precision diagnostics in urology, and this recognition underscores the momentum we are generating in the fight against prostate cancer. Thank you to our partners, clinical collaborators, and the broader urology community for your continued support.”
Stay tuned as we continue to make MiCheck® Prostate available to more practices nationwide.
